Q4 2023 · —
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$12.44M-$12.44M derivedno prior Q4 2022 on fileN/M vs Q3 2023
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Cash Flowderived-$8,036,000—
Free Cash Flowderived-$8,472,000—
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
no prior Q4 2022 on file
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bicara Therapeutics Inc. · CIK 2023658 · Engraved from SEC EDGAR